2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2824

Autoantibodies Against CD74 – a New Diagnostic Marker for Spondyloarthritis (SpA)
Abstract Number: 2825

Characterization of Mesenchymal Stem Cells Generated from Axial Spondyloarthritis Patient-Derived Induced Pluripotent Stem Cells
Abstract Number: 2826

Stimulation of Autophagy Reduces Misfolded HLA-B27 in a Rat Model of Spondyloarthritis
Abstract Number: 2827

Analysis of HLA-B27 Transgenic Rats Reveals Specific Gut Transcriptome and Microbiome Signatures Associated with Inflammation
Abstract Number: 2828

Profiling Immunogenic Bacteria within the Microbiota of ZAP-70 Mutant SKG Mice Associated with Spondyloarthritis and Ileitis Using IgA-SEQ
Abstract Number: 2829

Enhanced Expression of the Transcription Factor T-Bet Alters Pro-Inflammatory Cytokine Profile in Ankylosing Spondylitis
Abstract Number: 2830

Synovial Fluid T Cells of Patients with Reactive Arthritis and Undifferentiated Spondyloarthropathy Respond to Salmonella Typhimurium Outer Membrane Protein a and Induces IL17 and IL23 Production By Synovial Fluid Mononuclear Cells
Abstract Number: 2831

A Subset of Natural Killer Cells Are Expanded in Synovial Fluid of Patients with Reactive Arthritis and Undifferentiated Spondyloarthritis
Abstract Number: 2832

Characterization of Leukocyte Subsets in Ankylosing Spondylitis Patients
Abstract Number: 2833

Negative Regulator, MiR-23a, Down-Regulated in Psoriatic Arthritis. Implications for Disease Pathogenesis
Abstract Number: 2834

CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients
Abstract Number: 2835

Long-Term Improvements with Certolizumab Pegol in Joints and Extra-Articular Manifestations of Psoriatic Arthritis in Patients with and without Prior Anti-TNF Exposure
Abstract Number: 2836

Early Clinical Response Is a Better Predictor of Long-Term Remission Than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis
Abstract Number: 2837

Sulfasalazine Comedication: A Predictor of Reduced Long-Term Anti-TNF Switch in Ankylosing Spondylitis
Abstract Number: 2838

Evidence of Serological IL-23/IL-17 Axis Activation in Ankylosing Spondylitis Patients with Long-Term TNF Blockade: The Missing Therapy Target?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].